Inhibitory efficacy in platelet aggregation and pharmacokinetics of single oral administration of 300mg clopidogrel and 20mg prasugrel - Inhibitory efficacy in platelet aggregation and pharmacokinetics of clopidogrel and prasugrel

Kazuo Umemura Center for clinical research Hamamatsu University Hospital0 个研究点目标入组 50 人开始时间: 2014年8月1日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•1.History of liver diseases, cardiovascular diseases, respiratory diseaases, gastroenteric diseases, kidney diseases, cerebralvascular diseases, cancer 2.Known hypersensitivity to some drugs and foods 3.Under normal range in platelet counts at screning 4.Treatment by other doctors (included supplement) within 14 days before screening 5.Treatment with any investigational compound within 120 days before screening 6.History of blood taken *>= 1200ml of all blood within 1 year before screening *>= 400ml of all blood with 84 days before screening *>= 200ml of all blood within 14 days before screening 7.Known active chronic hepatitis B or C, active syphilis and human immunodeficiency virus infection 8.Abuse of alcohol or drugs (included past history) 9.Bleeding, in the tendency to bleeding, and family history and past history of bleeding disorders 10.During pregnancy and possibility of pregnancy and lactation period 11.Any serious medical or psychiatric illness that could, in the opinion of the investigator, potentially interfere with the completion of treatment according to this protocol.

发起方

Kazuo Umemura Center for clinical research Hamamatsu University Hospital